

Patrick H Nachman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5215059/publications.pdf>

Version: 2024-02-01

77
papers

5,791
citations

81743

39
h-index

76769

74
g-index

78
all docs

78
docs citations

78
times ranked

5320
citing authors

#	ARTICLE	IF	CITATIONS
1	C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study. CKJ: Clinical Kidney Journal, 2022, 15, 922-928.	1.4	30
2	Long-Term Outcomes of Kidney Transplant Recipients with Glomerulonephritides by Induction Type and Steroid Avoidance. Transplantation, 2022, 3, 68-82.	0.3	0
3	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney International, 2021, 99, 519-523.	2.6	4
4	Advances in ANCA-associated vasculitis and lupus nephritis. Nature Reviews Nephrology, 2021, 17, 89-90.	4.1	4
5	What Is the Best Maintenance Therapy for ANCA Vasculitis?. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1906-1908.	2.2	1
6	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.4	17
7	The Authors Reply. Kidney International Reports, 2020, 5, 1612-1613.	0.4	0
8	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	1.4	14
9	Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy. Kidney International Reports, 2020, 5, 706-717.	0.4	8
10	Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Arthritis Care and Research, 2020, 73, 1372-1378.	1.5	11
11	Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1228-1239.	0.4	5
12	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 1243-1249.	0.5	93
13	Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis. Kidney International Reports, 2019, 4, 1617-1629.	0.4	20
14	Using PROMIS® to create clinically meaningful profiles of nephrotic syndrome patients.. Health Psychology, 2019, 38, 410-421.	1.3	16
15	Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Associated Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1894-1903.	2.9	26
16	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	2.6	38
17	Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity. PLoS ONE, 2019, 14, e0213215.	1.1	29
18	Rituximab bioavailability in primary membranous nephropathy. Nephrology Dialysis Transplantation, 2019, 34, 1423-1425.	0.4	35

#	ARTICLE	IF	CITATIONS
19	Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2019, 4, 551-560.	0.4	14
20	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	2.1	68
21	Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. <i>Journal of Nephrology</i> , 2019, 32, 669-672.	0.9	14
22	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
23	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135
24	Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 469-481.	2.2	128
25	Persistent Hematuria in ANCA Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 201-202.	2.2	5
26	An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 414-421.	2.2	57
27	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39
28	Repeat kidney biopsy for lupus nephritis: an important step forward. <i>Kidney International</i> , 2018, 94, 659-661.	2.6	12
29	An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome. <i>American Journal of Human Genetics</i> , 2018, 103, 232-244.	2.6	147
30	Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 45, 248-256.	1.4	25
31	Interstitial lung disease in ANCA vasculitis. <i>Autoimmunity Reviews</i> , 2017, 16, 722-729.	2.5	109
32	Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina. <i>American Journal of Nephrology</i> , 2017, 45, 442-451.	1.4	19
33	The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy. <i>American Journal of Nephrology</i> , 2017, 45, 365-372.	1.4	14
34	Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811769255.	0.6	7
35	ANCA Glomerulonephritis and Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1680-1691.	2.2	238
36	Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1752-1759.	2.2	41

#	ARTICLE	IF	CITATIONS
37	Complete Remission in the Nephrotic Syndrome Study Network. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 81-89.	2.2	53
38	Patients with primary membranous nephropathy are at high risk of cardiovascular events. <i>Kidney International</i> , 2016, 89, 1111-1118.	2.6	55
39	Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 386-394.	2.2	47
40	Recent pathogenetic advances in ANCA-associated vasculitis. <i>Presse Medicale</i> , 2015, 44, e223-e229.	0.8	9
41	Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2930-2937.	3.0	68
42	Gleaning relapse risk from B cell phenotype: decreased CD5 ⁺ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1784-1786.	0.5	18
43	Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. <i>Kidney International</i> , 2014, 85, 1412-1420.	2.6	76
44	Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1211-1218.	0.4	64
45	Predictors of Treatment Outcomes in ANCA-Associated Vasculitis with Severe Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 905-913.	2.2	120
46	Decreased CD5 ⁺ B Cells in Active ANCA Vasculitis and Relapse after Rituximab. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 382-391.	2.2	82
47	Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 137-146.	0.4	25
48	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. <i>Kidney International</i> , 2013, 83, 749-756.	2.6	268
49	Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. <i>Journal of Clinical Investigation</i> , 2013, 123, 1773-1783.	3.9	204
50	Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 240-247.	2.2	106
51	Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. <i>Kidney International</i> , 2012, 81, 190-195.	2.6	159
52	Venous Thromboembolism in Patients with Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 43-51.	2.2	173
53	Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3452-3462.	6.7	335
54	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. <i>Transplantation</i> , 2011, 91, 1370-1375.	0.5	71

#	ARTICLE	IF	CITATIONS
55	Pathogenesis of Lung Vasculitis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 245-253.	0.8	9
56	Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. <i>Kidney International</i> , 2011, 80, 1339-1343.	2.6	35
57	Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. <i>Kidney International</i> , 2011, 80, 992-999.	2.6	12
58	Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1. <i>European Journal of Haematology</i> , 2010, 85, 257-263.	1.1	51
59	Rituximab Therapy in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2188-2198.	2.2	247
60	High Prevalence of Sickle Cell Trait in African Americans with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 413-417.	3.0	70
61	The clinical course of ANCA small-vessel vasculitis on chronic dialysis. <i>Kidney International</i> , 2009, 76, 644-651.	2.6	108
62	Which maintenance therapy for ANCA vasculitis?. <i>Nature Reviews Nephrology</i> , 2009, 5, 254-256.	4.1	6
63	Rituximab Therapy for Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 734-744.	2.2	80
64	Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. <i>Arthritis and Rheumatism</i> , 2008, 58, 2908-2918.	6.7	231
65	Maintenance of Tolerance by Regulation of Anti-myeloperoxidase B Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1763-1773.	3.0	9
66	Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case control study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3508-3515.	0.4	52
67	Similar CD19 Dysregulation in Two Autoantibody-Associated Autoimmune Diseases Suggests a Shared Mechanism of B-Cell Tolerance Loss. <i>Journal of Clinical Immunology</i> , 2007, 27, 53-68.	2.0	61
68	Various Forms of Life in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2006, 144, 377.	2.0	11
69	Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody-Associated Small-Vessel Vasculitis. <i>Annals of Internal Medicine</i> , 2005, 143, 621.	2.0	396
70	A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2725-2732.	0.4	103
71	Circumvention of Normal Constraints on Granule Protein Gene Expression in Peripheral Blood Neutrophils and Monocytes of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2103-2114.	3.0	83
72	Alternative therapies and future intervention for treatment of membranous nephropathy. <i>Seminars in Nephrology</i> , 2003, 23, 362-372.	0.6	14

#	ARTICLE	IF	CITATIONS
73	Long-term glycemic control measurements in diabetic patients receiving hemodialysis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 297-307.	2.1	138
74	Silica Exposure in Anti-Neutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis and Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 134-142.	3.0	154
75	Restriction in Vβ Gene Use and Antigen Selection in Anti-Myeloperoxidase Response in Mice. <i>Journal of Immunology</i> , 2000, 165, 3890-3897.	0.4	8
76	Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. <i>Kidney International</i> , 1999, 56, 1544-1550.	2.6	152
77	Mycophenolate Mofetil Therapy in Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 833-839.	3.0	206